Preliminary results of a phase Ⅱ prospective clinical study of early-stage nasal NK/T-cell lymphoma with extended involved-field intensity-modulated radiotherapy
10.3760/cma.j.issn.1004-4221.2015.04??006
- VernacularTitle:早期原发鼻腔 NK/T 细胞淋巴瘤局部扩大野IMRT 前瞻性Ⅱ期研究的初步结果
- Author:
Shaoqing NIU
;
Yujing ZHANG
;
Ge WEN
;
Yiyang LI
;
Lingling FENG
;
Hanyu WANG
;
Bixiu WEN
- Publication Type:Journal Article
- Keywords:
Extranodal Natural Killer/ T-cell lymphoma,nasal type/ intensity-modulated radiotherapy;
Extended involved-field;
Curative effect
- From:
Chinese Journal of Radiation Oncology
2015;(4):377-381
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the feasibility of the scheme of target volume delineation with extended involved?field intensity?modulated radiotherapy (IMRT) for patients with early?stage nasal NK/ T?cell lymphoma (NC?NKTL). Methods Twenty?one patients with stage IE?IIE NC?NKTL were treated with short?course chemotherapy combined with radiotherapy from 2011 to 2013. The majority of patients received the GELOX regimen. All patients received extended involved?field IMRT with a dose of 54?? 6 Gy in 26 fractions for gross tumor volume, 50?? 7 Gy in 26 fractions for high?risk clinical target volume (CTV), and 45?? 5 Gy in 26 fractions for low?risk CTV. The dose distribution, short?term treatment outcomes, and adverse reactions were analyzed. Results The 2?year sample size was 12. The 2?year follow?up rate was 100%. The 2?year local control rate ( LRC) was 100%. The 2?year overall and progression?free survival rates were 90?? 5% and 90?? 5%, respectively. The median coverage rates of planning target volumes with 90% of the prescribed doses of 54?? 6 Gy, 50?? 7 Gy, and 45?? 5 Gy were 99?? 8%, 99?? 6%, and 99?? 7%, respectively. No grade 3 or 4 adverse reactions were observed in patients. Conclusions The scheme of target volume delineation and dose configuration in our study not only achieves excellent target volume coverage, but also reduces adverse reactions in patients, which achieves a 2?year LRC ideal for patients with early?stage NC?NKTL.
